KR102228055B1 - 종양의 치료 또는 예방을 위한 병용 요법 - Google Patents

종양의 치료 또는 예방을 위한 병용 요법 Download PDF

Info

Publication number
KR102228055B1
KR102228055B1 KR1020197031149A KR20197031149A KR102228055B1 KR 102228055 B1 KR102228055 B1 KR 102228055B1 KR 1020197031149 A KR1020197031149 A KR 1020197031149A KR 20197031149 A KR20197031149 A KR 20197031149A KR 102228055 B1 KR102228055 B1 KR 102228055B1
Authority
KR
South Korea
Prior art keywords
compound
epoxytiglian
tumor
immune checkpoint
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197031149A
Other languages
English (en)
Korean (ko)
Other versions
KR20190126431A (ko
Inventor
폴 워렌 레델
제이슨 킹슬리 컬렌
글렌 매튜 보일
피터 고든 파슨스
빅토리아 앤 고든
Original Assignee
큐바이오틱스 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901027A external-priority patent/AU2017901027A0/en
Application filed by 큐바이오틱스 피티와이 리미티드 filed Critical 큐바이오틱스 피티와이 리미티드
Publication of KR20190126431A publication Critical patent/KR20190126431A/ko
Application granted granted Critical
Publication of KR102228055B1 publication Critical patent/KR102228055B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197031149A 2017-03-23 2018-03-23 종양의 치료 또는 예방을 위한 병용 요법 Active KR102228055B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017901027 2017-03-23
AU2017901027A AU2017901027A0 (en) 2017-03-23 Combination Therapy
PCT/AU2018/050277 WO2018170559A1 (en) 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours

Publications (2)

Publication Number Publication Date
KR20190126431A KR20190126431A (ko) 2019-11-11
KR102228055B1 true KR102228055B1 (ko) 2021-03-16

Family

ID=63583892

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031149A Active KR102228055B1 (ko) 2017-03-23 2018-03-23 종양의 치료 또는 예방을 위한 병용 요법

Country Status (27)

Country Link
US (1) US11213506B2 (https=)
EP (1) EP3600281B1 (https=)
JP (1) JP6905075B2 (https=)
KR (1) KR102228055B1 (https=)
CN (1) CN110461324A (https=)
AU (1) AU2018238202C1 (https=)
CA (1) CA3056685C (https=)
DK (1) DK3600281T3 (https=)
EA (1) EA201992220A1 (https=)
ES (1) ES2953575T3 (https=)
FI (1) FI3600281T3 (https=)
HR (1) HRP20230936T1 (https=)
HU (1) HUE063299T2 (https=)
IL (1) IL269522B2 (https=)
LT (1) LT3600281T (https=)
MX (1) MX391826B (https=)
MY (1) MY197427A (https=)
PH (1) PH12019502132A1 (https=)
PL (1) PL3600281T3 (https=)
PT (1) PT3600281T (https=)
RS (1) RS64472B1 (https=)
SG (1) SG11201907891XA (https=)
SI (1) SI3600281T1 (https=)
SM (1) SMT202300272T1 (https=)
UA (1) UA125614C2 (https=)
WO (1) WO2018170559A1 (https=)
ZA (1) ZA201906001B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006326872C1 (en) * 2005-12-23 2018-05-17 QBiotics Pty Ltd Tiglien-3-one derivatives
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
US12357959B2 (en) 2018-12-26 2025-07-15 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
EP3952858B1 (en) * 2019-04-12 2025-12-17 QBiotics Pty Ltd Method of treating tumours
MX2021015673A (es) 2019-06-19 2022-02-03 QBiotics Pty Ltd Alteracion de biopelicula.
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2022548309A (ja) 2019-09-23 2022-11-17 ツイスト バイオサイエンス コーポレーション Ｃｒｔｈ２のバリアント核酸ライブラリー
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
IL293670A (en) 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
WO2022159620A1 (en) 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
KR102774792B1 (ko) 2021-05-06 2025-03-05 한국과학기술연구원 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
MX2024010046A (es) * 2022-02-17 2024-08-26 QBiotics Pty Ltd Terapias de combinacion.
JP2026500534A (ja) * 2022-12-21 2026-01-07 キューバイオティクス プロプライアタリー リミティド 結晶形態及びその製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070985A1 (en) 2005-12-23 2007-06-28 Qbiotics Limited Tiglien-3-one derivatives
CN104926758A (zh) 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268148B2 (en) * 2005-07-13 2012-11-01 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
RS58532B1 (sr) 2013-04-18 2019-04-30 Qbiotics Ltd Metodi i kompozicije za zarastanje rana
WO2015133596A1 (ja) * 2014-03-07 2015-09-11 国立大学法人京都大学 細胞培養用組成物
AU2015289081B2 (en) 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
JP6991857B2 (ja) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
CN108026026B (zh) * 2015-08-03 2021-02-09 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸和类似物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070985A1 (en) 2005-12-23 2007-06-28 Qbiotics Limited Tiglien-3-one derivatives
CN104926758A (zh) 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, 9(10), e108887, 2014.

Also Published As

Publication number Publication date
IL269522A (https=) 2019-11-28
ES2953575T3 (es) 2023-11-14
MX2019011221A (es) 2019-11-01
NZ756754A (en) 2024-02-23
HRP20230936T1 (hr) 2023-11-24
AU2018238202C1 (en) 2025-06-05
PL3600281T3 (pl) 2023-09-11
CA3056685A1 (en) 2018-09-27
UA125614C2 (uk) 2022-05-04
CN110461324A (zh) 2019-11-15
EP3600281A1 (en) 2020-02-05
AU2018238202A8 (en) 2024-03-28
RS64472B1 (sr) 2023-09-29
AU2018238202B2 (en) 2024-03-28
SG11201907891XA (en) 2019-09-27
US20200030279A1 (en) 2020-01-30
SI3600281T1 (sl) 2023-10-30
ZA201906001B (en) 2023-12-20
WO2018170559A1 (en) 2018-09-27
JP2020511512A (ja) 2020-04-16
CA3056685C (en) 2024-01-16
MY197427A (en) 2023-06-16
DK3600281T3 (da) 2023-08-14
IL269522B1 (en) 2024-01-01
HUE063299T2 (hu) 2024-01-28
PT3600281T (pt) 2023-09-04
EP3600281A4 (en) 2020-03-18
SMT202300272T1 (it) 2023-09-06
EP3600281B1 (en) 2023-05-31
KR20190126431A (ko) 2019-11-11
US11213506B2 (en) 2022-01-04
EA201992220A1 (ru) 2020-02-11
LT3600281T (lt) 2023-09-11
MX391826B (es) 2025-03-21
JP6905075B2 (ja) 2021-07-21
FI3600281T3 (fi) 2023-08-24
PH12019502132A1 (en) 2020-07-06
AU2018238202A1 (en) 2019-09-19
IL269522B2 (en) 2024-05-01
BR112019019748A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
KR102228055B1 (ko) 종양의 치료 또는 예방을 위한 병용 요법
TW201842921A (zh) 治療性ｒｎａ
US10130590B2 (en) Methods of treating cancer with atovaquone-related compounds
US12226391B2 (en) Method of treating tumours
Wang et al. A chemical conjugation of JQ‐1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation
AU2019398198B2 (en) CXCR7 inhibitors for the treatment of cancer
Zuo et al. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer
TWI614029B (zh) 新穎醫藥組成物及其用途
JP7044803B2 (ja) 癌の治療のための化合物、組成物およびその使用
EA044756B1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
HK40014624B (en) Combination therapy for the treatment or prevention of tumours
HK40014624A (en) Combination therapy for the treatment or prevention of tumours
BR112019019748B1 (pt) Usos de um composto de epóxitigliano ou um sal farmaceuticamente aceitável do mesmo, usos de um inibidor do ponto de verificação imunológico e kit
WO2025217270A1 (en) METHODS OF TREATMENT USING TGFb-RECEPTOR 1 INHIBITION AND LTBR AGONISM
EA044461B1 (ru) Способ лечения опухолей
HK40060616A (en) Method of treating tumours
HK40060616B (en) Method of treating tumours

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5